1. Home
  2. RGLS vs SPPP Comparison

RGLS vs SPPP Comparison

Compare RGLS & SPPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • SPPP
  • Stock Information
  • Founded
  • RGLS 2007
  • SPPP 2011
  • Country
  • RGLS United States
  • SPPP Canada
  • Employees
  • RGLS N/A
  • SPPP N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • SPPP
  • Sector
  • RGLS Health Care
  • SPPP
  • Exchange
  • RGLS Nasdaq
  • SPPP NYSE
  • Market Cap
  • RGLS 106.7M
  • SPPP 115.9M
  • IPO Year
  • RGLS 2012
  • SPPP N/A
  • Fundamental
  • Price
  • RGLS $1.59
  • SPPP $10.77
  • Analyst Decision
  • RGLS Strong Buy
  • SPPP
  • Analyst Count
  • RGLS 6
  • SPPP 0
  • Target Price
  • RGLS $10.33
  • SPPP N/A
  • AVG Volume (30 Days)
  • RGLS 391.3K
  • SPPP 408.6K
  • Earning Date
  • RGLS 11-11-2024
  • SPPP 01-01-0001
  • Dividend Yield
  • RGLS N/A
  • SPPP N/A
  • EPS Growth
  • RGLS N/A
  • SPPP N/A
  • EPS
  • RGLS N/A
  • SPPP N/A
  • Revenue
  • RGLS N/A
  • SPPP N/A
  • Revenue This Year
  • RGLS N/A
  • SPPP N/A
  • Revenue Next Year
  • RGLS N/A
  • SPPP N/A
  • P/E Ratio
  • RGLS N/A
  • SPPP N/A
  • Revenue Growth
  • RGLS N/A
  • SPPP N/A
  • 52 Week Low
  • RGLS $1.08
  • SPPP $8.55
  • 52 Week High
  • RGLS $3.79
  • SPPP $11.39
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 53.16
  • SPPP 60.30
  • Support Level
  • RGLS $1.39
  • SPPP $10.21
  • Resistance Level
  • RGLS $1.68
  • SPPP $11.39
  • Average True Range (ATR)
  • RGLS 0.12
  • SPPP 0.18
  • MACD
  • RGLS 0.01
  • SPPP 0.08
  • Stochastic Oscillator
  • RGLS 68.97
  • SPPP 63.79

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About SPPP SPROTT PHYS PLATINUM & PALLADIUM

Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.

Share on Social Networks: